PHAT logo

PHATHOM PHARMACEUTICALS INC

PHATNASDAQ
๐Ÿ† #2841 by market capEarnings Oct 28US Equity
$7.35โ–ผ $0.01 (โˆ’0.09%)
Live
๐Ÿ””
Track PHAT
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 0.1%
7dโ–ฒ 5.3%
14dโ–ผ 4.4%
30dโ–ผ 23.1%
ytdโ–ผ 55.7%
1yโ–ผ 37.5%
๐ŸฆMarket Cap
$595M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+216.9%
High Growth
๐Ÿ“ŠGross Margin
82.9%
High
๐Ÿ’ตFCF Margin
-15.3%
Thin
โš–๏ธP/S Ratio
2.5x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$7.27 โ€“ $7.40
52-Week Range
$6.91 โ€“ $18.31
Volume
$2.13B
Avg Volume
$2.40B
Shares Outstanding
80.9M
Next Earnings
Nov 8, 2026

Fundamentals Snapshot

Annual Revenue
$175M
Last Q Revenue
$74M
P/E Ratio
-5.7
P/S Ratio
2.5x
EPS (TTM)
$-1.18
Dividend Yield
0.00%
Dilution (1yr)
+3.9%

Why Investors Own PHAT

  • โœ“High-growth profile โ€” revenue up +46.0% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 47% gross margin and 29% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PHAT logo

PHATHOM PHARMACEUTICALS INC

PHAT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$175Mโ–ฒ +216.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
87.1%โ–ฒ +1.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
โˆ’$160Mโ–ผ โˆ’42.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
โˆ’$167Mโ–ผ โˆ’37.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
73.8Mโ–ฒ +3.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
โˆ’$82Mโ–ผ โˆ’$177M YoY
StockOtter ยท stockotter.space

About PHATHOM PHARMACEUTICALS INC

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
60/100

Analyst Ratings

โ“˜
Consensus
Buy
17 analysts
Strong Buy6
Buy9
Hold2
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

GlobeNewsWireยท1d ago

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNAยฎ (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

Initiation of registrational Phase 3 study of VOQUEZNAยฎ (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first

Defense Worldยท13d ago

Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low โ€“ Time to Sell?

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report)'s stock price hit a new 52-week low during trading on Thursday. The stock traded as low as $7.66 and last traded at $7.69, with a volume of 2071393 shares tr

GuruFocusยท13d ago

PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law

[url="]Schall, Brown and Schwartz LLP[/url] (รขย€ยœSBSรขย€ย), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv

GlobeNewsWireยท29d ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseas

GlobeNewsWireยทAug 4

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals' revised FY 2026 revenue outlook of $310 million -- $325 million came in below the roughly $332 million -- $334 million analysts were modeling, and PHAT shares sold off on the news Phathom Pharmac

Business WireยทAug 3

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

NEW YORK--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses after the Company lowered its full-year 2026 revenue guidance to $310 millionโ€“$325 million from its previously issued $320